BEIJING, Nov. 24 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.
(OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and
producer of prescriptions drugs and licensed national seller of pharmaceutical
products in the People's Republic China, today reported it will exhibit at the
62nd PHARMCHINA as a member of the Beijing pharmaceutical delegation.
Time: November 26-28, 2009
Venue: International Convention Center, Chengdu
The Beijing delegation features more than twenty pharmaceutical companies from Beijing, including Beijing Shuanghe Group, Beijing Pharmaceutical Group, and Tongrentang. As a member of the delegates, Lotus will continue to market its drugs that have established certain market share in China and introduce three potential new drugs that are subject to the State Food and Drug Administration's approval. These drugs include Laveo-Bambutero for asthma, Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.
About PHARMCHINA
PHARMCHINA is the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.
Advertisement
Time: November 26-28, 2009
Venue: International Convention Center, Chengdu
Advertisement
The Beijing delegation features more than twenty pharmaceutical companies from Beijing, including Beijing Shuanghe Group, Beijing Pharmaceutical Group, and Tongrentang. As a member of the delegates, Lotus will continue to market its drugs that have established certain market share in China and introduce three potential new drugs that are subject to the State Food and Drug Administration's approval. These drugs include Laveo-Bambutero for asthma, Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.
About PHARMCHINA
PHARMCHINA is the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
Tel: +86-10-6389-9868
Email: [email protected]
SOURCE Lotus Pharmaceuticals, Inc.